TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
August 08 2022 - 6:50AM
Business Wire
-Executive Management to Host Conference Call
on August 15, 2022, at 8:30 a.m. ET-
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD),
an innovative, leading women’s healthcare company, today announced
that it will report its second quarter 2022 financial results on
Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the
U.S. financial markets.
Executive management will host a conference call and webcast to
discuss the results and provide a business update as follows:
Date:
Monday, August 15, 2022
Time:
8:30 a.m. ET
Audio Conference Line
https://register.vevent.com/register/BI7d111b66df2f4e8f849bb6048c1fa4d1
Webcast Link:
https://edge.media-server.com/mmc/p/trnoknyx
A live webcast and audio archive for the event may be accessed
on the home page or from the “Investors & Media” section of the
TherapeuticsMD website at www.therapeuticsmd.com. Please connect to
the website prior to the start of the presentation to ensure
adequate time for any software downloads that may be necessary to
listen to the webcast. A replay of the webcast will be archived on
the website for at least 30 days. In addition, a digital recording
of the conference call will be available for replay in the
“Investors & Media” section of the TherapeuticsMD website at
www.therapeuticsmd.com.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. TherapeuticsMD’s products are designed to
address the unique changes and challenges women experience through
the various stages of their lives with a therapeutic focus in
family planning, reproductive health, and menopause management.
TherapeuticsMD is committed to advancing the health of women and
championing awareness of their healthcare issues. To learn more
about TherapeuticsMD, please visit therapeuticsmd.com or follow us
on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD’s
objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments
that the company intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are
often characterized by terminology such as "believes," "hopes,"
"may," "anticipates," "should," "intends," "plans," "will,"
"expects," "estimates," "projects," "positioned," "strategy" and
similar expressions and are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company’s control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in
the company’s filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, and include
the following: whether the Company will be able to refinance the
indebtedness under its term loan facility, and, if not, whether the
Company will be able to continue as a going concern; whether the
Company will be able to raise capital to fund its operations; the
effects of the COVID-19 pandemic; the Company’s ability to maintain
or increase sales of its products; the Company’s ability to develop
and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain
additional financing necessary therefor; the effects of supply
chain issues on the supply of the Company’s products; the potential
of adverse side effects or other safety risks that could adversely
affect the commercialization of the company’s current or future
approved products or preclude the approval of the Company’s future
drug candidates; the Company’s ability to protect its intellectual
property; the length, cost and uncertain results of future clinical
trials; the Company’s reliance on third parties to conduct its
manufacturing, research and development and clinical trials; the
ability of the Company’s licensees to commercialize and distribute
the Company’s products; the ability of the Company’s marketing
contractors to market ANNOVERA; the availability of reimbursement
from government authorities and health insurance companies for the
Company’s products; the impact of product liability lawsuits; the
influence of extensive and costly government regulation; the impact
of leadership transitions; the volatility of the trading price of
the Company’s common stock.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220808005173/en/
Lisa M. Wilson In-Site Communications, Inc. 212-452-2793
lwilson@insitecony.com
TherapeuticsMD 561-961-1900 IR@TherapeuticsMD.com
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Apr 2023 to Apr 2024